FDA Releases Draft Guidance on Residual Solvents in US-Approved Drug Products

Summary

The US Food and Drug Administration (FDA) has made available a draft guidance document outlining its recommendations for controlling residual solvents in pharmaceuticals approved for sale in the United States, following a change to the US Pharmacopeia's testing requirements.